India Diabetes Market Growth Analysis - Forecast Trends and Outlook (2025-2034)

The India diabetes market size was valued at INR 316.00 Billion in 2024, driven by high prevalence of diabetes cases across the region. The market is expected to grow at a CAGR of 16.00% during the forecast period of 2025-2034, to reach INR 1.39 trillion by 2034.

Diabetes: Introduction

Diabetes is a condition where the body cannot use the insulin produced effectively or the pancreas does not produce enough insulin at all. Insulin is a hormone produced to regulate glucose in the body. There are two categories of diabetes, type 1 and type 2. Type 1 diabetes is based on the amount of insulin produced by the body and type 2 diabetes is based on the management of insulin by the body. Common symptoms include frequent thirst, blurred vision, fatigue, unintentional weight loss and constant urge to urinate.

India Diabetes Market Analysis

The diabetes incidence rate in India stands at around 10.1 crores in 2023. The India diabetes market value is driven by the rising awareness among the patients about the symptoms of diabetes, and its ill effects on health, which has majorly intensified the diagnosis and increased the drug treatment rates in the country.

Rapid urbanization and developing healthcare infrastructure are also aiding the industry growth of diabetes in India. In addition to this, extending pharmaceutical contract manufacturing, low-cost drug production, and the introduction of advanced technologies have further accelerated the growth of diabetes market in India. In July 2023, the Indian Institute of Technology (IIT) Bhilai and Shiv Nadar University revealed “smart insulin”, which contains an extended period of insulin release that lasts up to 2 days, far greater than the average 12-hour duration of regular insulin.

To meet the high India diabetes market demand, leading health platforms for diabetes like the BeatO App have announced their physical clinic collaborations. After launching 5 clinics across Delhi-NCR, the company visions to spread across Uttar Pradesh, Madhya Pradesh, Rajasthan, Gujarat, and Odisha in the next 6 months. Akums Drugs and Pharmaceuticals Limited also received approval for its triple combination diabetes treatment which includes Sitagliptin 100, Pioglitazone 15 and Metformin 1000/500. Therefore, the market is expected to witness significant growth in the forecast period.

India Diabetes Market Segmentation

Market Breakup by Type:

• Type 1 Diabetes
• Type 2 Diabetes

Market Breakup by Treatment Type:

• Insulin-Based
• Non-Insulin-Based
• Others

Market Breakup by Doses Form:

• Tablets and Capsules
• Injections
• Creams and Gels
• Others

Market Breakup by Route of Administration:

• Oral
• Parenteral

Market Breakup by End User:

• Hospitals
• Speciality Clinics
• Homecare Settings
• Others

Market Breakup by Distribution Channel

• Hospitals Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

India Diabetes Market Overview

The India diabetes market growth is driven by the launch of programs like National Program for Prevention and Control of Non-Communicable Diseases (NP-NCD), which has been launched by the government of India and works on delivering glucometer and drugs for diabetes to the patients. As a part of this program, the region is also experiencing the set-up of new district clinics and community health centers to promote early diagnosis and prevention of the condition. Movements like Fit India, Khelo India and several yoga related activities are also promoted by the Ministry of AYUSH to promote physical activity in all generations.

Moreover, the increasing partnerships amongst private and state-owned entities will also contribute significantly to the India diabetes market share and deliver better solutions to diabetic and pre-diabetic patients. Promotional activities to eat healthy are also advocated by prominent institutions like FSSAI. Eat Right Initiative, Safe and Nutritious Food at Home and ‘Aaj se thoda kum' awareness initiatives are some of the prime examples. Under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), the masses are also set to receive generic medicines like insulin at affordable prices.

India Diabetes Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Sun Pharmaceutical Industries Ltd.
• Biocon Limited
• Dr. Reddy's Laboratories Ltd.
• Novo Nordisk India Pvt. Ltd.
• Sanofi India Limited
• Eli Lilly and Company (India) Pvt. Ltd.
• Johnson & Johnson Private Limited
• Abbott India Limited
• Glenmark Pharmaceuticals Ltd.
• AstraZeneca Pharma India Limited
• Lupin Limited
• Torrent Pharmaceuticals Ltd.
• Merck Limited
• Cadila Healthcare Limited
• Wockhardt Limited

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

More Insights On:

Type 2 Diabetes Mellitus Treatment Market Philippines Diabetes Care Devices Market Smart Diabetes Management Market Canada Diabetes Market Type 2 Diabetes Market Type 1 Diabetes Market China Diabetes Market Diabetes Drugs Market

This product will be delivered within 3-5 business days.